CHICAGO--(BUSINESS WIRE)--Antares today announced a record year for the firm closing more than 360 transactions in 2021 and issuing nearly $31 billion in financing commitments to middle market private ...
CHICAGO--(BUSINESS WIRE)--Antares today announced that it closed 139 transactions totaling almost $11 billion in financing commitments to middle market private equity-backed companies in the first ...
Ladies and gentlemen, welcome to the Antares Pharma Fourth Quarter and Full Year 2021 Financial and Operating Results Conference Call. Throughout today's recorded presentation, all participants will ...
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue ...
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial ...
Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., ...
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue ...
EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today reported financial and operating results for the second ...
¹ Denotes non-GAAP financial measure. Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback